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Molluskan hemocyanins are enormous oxygen-carrier glycoproteins that show remark-
able immunostimulatory properties when inoculated in mammals, such as the generation 
of high levels of antibodies, a strong cellular reaction, and generation of non-specific 
antitumor immune responses in some types of cancer, particularly for superficial blad-
der cancer. These proteins have the ability to bias the immune response toward a Th1 
phenotype. However, despite all their current uses with beneficial clinical outcomes, a 
clear mechanism explaining these properties is not available. Taking into account reports 
of natural antibodies against the hemocyanin of the gastropod Megathura crenulata 
[keyhole limpet hemocyanin (KLH)] in humans as well as other vertebrate species, we 
report here for the first time, the presence, in sera from unimmunized healthy donors, 
of antibodies recognizing, in addition to KLH, two other hemocyanins from gastropods 
with documented immunomodulatory capacities: Fisurella latimarginata hemocyanin 
(FLH) and Concholepas concholepas hemocyanin (CCH). Through an ELISA screening, 
we found IgM and IgG antibodies reactive with these hemocyanins. When the capacity 
of these antibodies to bind deglycosylated hemocyanins was studied, no decreased 
interaction was detected. Moreover, in the case of FLH, deglycosylation increased anti-
body binding. We evaluated through an in vitro complement deposition assay whether 
these antibodies activated the classical pathway of the human complement system. 
The results showed that all three hemocyanins and their deglycosylated counterparts 
elicited this activation, mediated by C1 binding to immunoglobulins. Thus, this work con-
tributes to the understanding on how the complement system could participate in the 
immunostimulatory properties of hemocyanins, through natural, complement-activating  
Abbreviations: KLH, keyhole limpet hemocyanin; Ox-KLH, deglycosylated (oxidized) KLH; FLH, Fissurella latimarginata 
hemocyanin; Ox-FLH, deglycosylated (oxidized) FLH; CCH, Concholepas concholepas hemocyanin; Ox-CCH, deglycosylated 
(oxidized) CCH.
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inTrODUcTiOn
Hemocyanins, present in some mollusks, are respiratory gly-
coproteins, found freely dissolved in the hemolymph of these 
organisms (1), where they are also involved in immune functions 
(2). Unlike hemoglobin, hemocyanins bind oxygen through 
copper (II) atoms, leading to their characteristic blue color (1, 
3). Depending on the organism, hemocyanins can be found 
arranged commonly into decamers, didecamers, and tridecamers, 
with a “hollow cylinder” configuration, although more recently, 
megatridecamers, with a “filled cylinder” shape, have also been 
reported (4, 5).
Hemocyanins are highly glycosylated [up to 9% in weight 
(1)], and among the most studied is the keyhole limpet hemo-
cyanin (KLH, from the gastropod Megathura crenulata), with 
immunostimulatory properties described around 50  years ago 
(1). These properties have led to its use in many applications, 
including experimental antigen, assessment of immunocompe-
tence in humans, carrier for antibody generation against diverse 
hapten molecules and peptides, diagnostic tool for the parasite 
Schistosoma mansoni, unspecific immunostimulant, and adjuvant 
in various vaccine formulations (6). Of special interest is its use 
in superficial bladder carcinoma, where intravesical instillation 
delivers better results than the classical treatment with bacillus 
Calmette-Guérin and with less side effects (7).
However, more recently, we have described Concholepas 
concholepas hemocyanin [CCH (8)] from the Loco or Chilean 
abalone and Fissurella latimarginata hemocyanin [FLH (9)], from 
the Lapa negra, gastropod mollusks found along the Pacific coasts 
of Chile and Perú. These hemocyanins possess immunogenicity 
and antitumor immunostimulatory properties, equal to or better 
than those of KLH (10, 11). CCH has been used as a carrier for 
antibody generation (12–15), as an experimental antigen (16, 17); 
as a carrier for an anti-prion vaccine (18), an immunocontracep-
tive vaccine (19); and more recently, as an adjuvant in a phase I 
trial for a dendritic cell vaccine against prostate cancer (20) In 
spite of this, the molecular mechanisms behind these remarkable 
properties remain elusive. Some previous explanations, invoking 
characteristics such as elevated size or quasi-D5 symmetry, do 
not seem now entirely satisfactory since isolated subunits have 
the same effect or can even outperform the whole molecules in 
some aspects (21, 22). Other explanations are their xenogenicity, 
their increased permanence time inside antigen-presenting cells 
as recently proposed by us (11), and their high carbohydrate 
content.
Although KLH glycosylation profiles are relatively well known, 
studies in the matter have not provided a definitive answer with 
regard to their role in immunogenicity/antigenicity. Early studies 
showed that KLH has carbohydrate epitopes that can cross-react 
with tumor antigens, leading to the antitumor effect observed 
for KLH (23). More recent studies show that KLH induces the 
activation and maturation of human dendritic cells, and that 
these properties are partially mediated by the mannose receptor, 
which can be explained by the presence in KLH of mannose and 
fucose, ligands of this receptor (24), as well in CCH and FLH, 
where mannose receptor mediated their endocytosis in murine 
peritoneal macrophages (25). By contrast, our previous work 
has shown that deglycosylation of FLH decreases its antitumor 
activity (9), while in CCH does not affect it and it even increases 
its immunogenicity (11).
Natural antibodies in experimental animals (26), birds 
(27–29), cattle (30, 31), and humans (26, 32, 33) bind to KLH, 
thus explaining, at least partially, the immunomodulatory 
properties of hemocyanins. These antibodies may activate the 
complement system, with consequences in innate and adaptive 
arms of the immune response (34, 35). C1, a pattern recognition 
receptor present in the serum of vertebrates, initiates the clas-
sical pathway of the complement system by detecting antigen-
bound antibodies, leading to the sequential activation of its 
serine-proteases C1r and C1s. The latter then cleaves C2 and 
C4, thus generating classical pathway C3 convertases which lead 
to terminal pathway activation and generation of membrane 
attack complexes which lyse the target cell (34, 35). During this 
activation, proinflammatory, opsonizing, and immunostimula-
tory functions are also generated, all of them highly relevant in a 
normal immune response (34). Together with the lectin pathway 
(MBL and ficolins) and the alternative pathway, this system pro-
vides a very important defense against bacterial cells, viruses, 
and transformed cells (35).
The presence of natural antibodies against one hemocyanin 
(KLH) has been known for some time now (26, 33). However, 
studies on possible connections between these antibodies and 
complement are scarce and need to be revisited under the 
present state of knowledge of this system. KLH has been used 
as a model antigen in a study of complement activation (36), 
but the complement-activating capacity of other hemocyanins 
has not been addressed. Moreover, the conditions described 
in a previous study do not discriminate between the classical 
and the lectin pathways as sources of the observed complement 
deposition (36).
For these reasons, we propose that natural antibodies against 
CCH and FLH (similar to natural anti-KLH antibodies), are 
detectable in healthy donors and that they specifically activate 
the classical pathway of the complement system. Accordingly, 
IgG and IgM antibodies were detected, being able to recognize all 
three hemocyanins mostly through non-glycosylated sites. These 
antibodies reacting with these proteins. Although a role for carbohydrates cannot be 
completely ruled out, in our experimental setting, glycosylation status had a limited effect. 
Finally, our data open possibilities for further studies leading to the design of improved 
hemocyanin-based research tools for diagnosis and immunotherapy.
Keywords: molluskan hemocyanins, complement system, natural antibodies, classical pathway, carbohydrates, 
adjuvants
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antibodies activated in vitro the classical pathway of the comple-
ment system, offering at least a partial explanation for the remark-
able immunomodulatory properties of these glycoproteins.
MaTerials anD MeThODs
hemocyanins
Lyophilized KLH (in PBS, 0.1 M sodium phosphate, 0.15 M NaCl, 
pH 7.2 after reconstitution) was obtained from Thermo Scientific 
(Waltham, MA, USA). CCH and FLH, isolated and purified under 
sterile and pyrogen-free conditions, were provided by Biosonda 
Company (Santiago, Chile). KLH was first reconstituted in dis-
tilled water and then all hemocyanins were diluted with PBS to 
desired concentrations. To obtain deglycosylated hemocyanins, 
oxidation with periodate was performed, as reported previously 
by us (11). Briefly, 15 mM sodium periodate (Merck, Germany) 
in 0.1 M sodium acetate buffer was prepared, adjusted to pH 5.5, 
and used to dilute the different hemocyanins to 0.5 mg/ml. They 
were then incubated for 1 h, in the dark, at room temperature 
and finally an excess of ethylene glycol was added to consume 
the remaining periodate by overnight incubation. Then, the 
deglycosylated hemocyanins (termed Ox-KLH, Ox-CCH, and 
Ox-FLH) were concentrated using the Amicon Ultra-4 10K 
(Merck) system, its concentration determined by the Bradford 
method (37) and diluted in PBS to desired concentrations.
Patient and Donor sera
Sera from patients P80 and P202, corresponding to an adult male 
and an adult female, respectively, who received immunotherapy 
against melanoma [consisting of tumor antigen-pulsed dendritic 
cells TAPCells (38, 39) and KLH as an adjuvant], were used as 
positive controls for the presence of antibodies against KLH. 
Blood was also obtained from five healthy adult donors D1 to 
D5 (three females and two males) with no diagnosis of chronic 
conditions and not subjected to present or past active immuniza-
tions with molluskan hemocyanins. Decomplemented serum was 
obtained by heat inactivation at 56°C, for 30 min.
assessment of human antibody Binding 
to Molluskan hemocyanins
Ninety-six-well polystyrene microplates were incubated with 
the different hemocyanins (native and deglycosylated) and with 
casein as a negative control, all at 10  µg/ml in PBS, through 
overnight incubation at 4°C. After washing with PBS, 0.05% 
Tween-20 (PBS-T), active solid phase sites were blocked with a 
2.5% w/v casein (Winkler, Santiago, Chile) solution with a pH of 
7.0, at 37°C for 2 h. Then, dilutions of 1:100 of decomplemented 
sera from patients and healthy donors, in blocking solution were 
incubated at 37°C for 1 h. Rabbit anti-human immunoglobulins 
(Amersham Biosciences, Buckinghamshire, UK), goat anti-
human IgG (specific for Fcγ chain, Sigma-Aldrich, St. Louis, 
MO, USA), or goat anti-human IgM (specific for Fc5µ fragments, 
Jackson ImmunoResearch, West Grove, PA, USA), all coupled 
to peroxidase, were added diluted in PBS-T. The reaction was 
developed with ABTS and 0.1% H2O2, and read at 405 nm after 
20 min of reaction.
assessment of complement classical 
Pathway activation by Molluskan 
hemocyanins
Microplates were sensitized as indicated above, and wells with 
purified human IgM (Jackson ImmunoResearch) at a concentra-
tion of 2 µg/ml, were also included, followed by washings with 
Tris-buffered saline (TBS) with 0.05% Tween-20 and 5  mM 
CaCl2 (TBS-T-Ca2+). Casein was used for blocking, and diluted 
sera from unimmunized donors were added. Then, the wells were 
incubated with purified human C1 (CompTech, Tyler, TX, USA) 
at 200  ng/ml in Veronal-buffered saline (VBS; 5  mM sodium 
diethylbarbiturate, 140 mM NaCl, 0.5 mM MgCl2, and 0.15 mM 
CaCl2) and then with C4 (CompTech), at 1 µg/ml, also in VBS. 
Then, a goat anti-human C4 antibody (CompTech) was added 
diluted in 2.5% casein, followed by a rabbit anti-goat IgG coupled 
to peroxidase (Calbiochem, Billerica, MA, USA), diluted in 
TBS-T-Ca2+. Finally, the reaction was developed with ABTS and 
0.1% H2O2 and read at 405 nm after 5 min of reaction. EDTA was 
used in some experiments at a 20 mM concentration and an anti-
C1q antibody [anti-C1q-85 (40), kindly provided by Dr. Diana 
Wouters, Immunopathology Department, Sanquin Blood Supply 
Foundation, Amsterdam, The Netherlands] was used at 2 µg/ml.
ethics statement
This study was carried out in accordance with the recommenda-
tions of the National Commission for Science and Technology 
(CONICYT) guidelines. All subjects gave written informed con-
sent in accordance with the Declaration of Helsinki. The protocol 
was approved by the Bioethical Committee for Human Research 
of the University of Chile.
statistical analysis
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) 
was used to process and analyze data and results. Statistical 
analysis was performed by means of a two-tailed Student’s t-test 
for both antibody detection and classical pathway activation 
assays. All experiments were replicated at least three times with 
representative results shown.
resUlTs
antibodies That recognize Diverse 
Molluskan hemocyanins are Present in 
human healthy Donors
According to previous reports (26, 33), we found antibodies 
recognizing KLH in the five unimmunized donors. We also 
found antibodies (total immunoglobulins) that recognized 
hemocyanins with recently described biomedical potential, such 
as FLH and CCH (Figure 1). This is the first report on natural 
antibodies against molluskan hemocyanins other than KLH. The 
positive anti-KLH control sera (P80), obtained from a mela-
noma patient immunized with tumor antigen-pulsed dendritic 
cells TAPCells (38, 39) and KLH as an adjuvant, also reacted 
with CCH and KLH. Then, we performed the same assays for 
donors D1, D3, and D5 (since they consistently showed higher 
FigUre 1 | Unimmunized donors present natural antibodies against 
molluskan hemocyanins. The levels of immunoglobulins specifically 
binding to keyhole limpet hemocyanin (KLH), Fissurella latimarginata 
hemocyanin (FLH), and Concholepas concholepas hemocyanin (CCH) were 
determined by an indirect ELISA in sera from five unimmunized donors, at a 
dilution of 1:100. Serum from a patient immunized with KLH (P80) was used 
as positive control. Bars represent the mean of three wells with the respective 
SD. The figures in this work are representative of at least three independent 
experiments. **p ≤ 0.01; ***p ≤ 0.001, assessed by a two-tailed Student’s 
t-test.
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reactivity) but using deglycosylated hemocyanins, since it is 
accepted that natural antibodies usually present broad specific-
ity for carbohydrates. Interestingly, although deglycosylation 
sometimes decreased antibody binding, especially for KLH in 
donor D3, in some cases, deglycosylation markedly increased 
antibody binding, especially in deglycosylated (oxidized) FLH 
(Ox-FLH) (Figure 2).
In order to assess the nature of these antibodies, we studied 
the binding of IgM class antibodies, classically described as 
the most common natural antibodies (41), using a specific 
antibody against IgM. Figure 3 shows that all donors presented 
IgM antibodies against native and deglycosylated hemocya-
nins. As previously observed, deglycosylation did not decrease 
antibody binding in any case, leading to a consistent increase 
in binding to Ox-FLH and to a lesser degree to deglycosylated 
(oxidized) KLH (Ox-KLH).
We then studied specific IgG binding to native and degly-
cosylated hemocyanins. Figure  4 shows that two donors (D3 
and D5) showed the highest IgG reactivity against KLH and 
CCH, respectively, although lower than those shown for IgM. 
Differently from IgM, deglycosylation strongly decreased IgG 
binding to control levels in D3 and D5. D5 was the only donor 
who presented a change on total immunoglobulin levels against 
CCH after deglycosylation, and this was not associated to a 
change in IgM levels, but to the mentioned decrease in IgG levels.
Molluskan hemocyanins activate the 
classical Pathway of the human 
complement system through antibodies 
Present in healthy Donors
We then used a C4b deposition assay to assess classical path-
way activation by molluskan hemocyanins. We used serum 
from donors D1, D3, and D5 as a source of antibodies, since 
these donors presented both IgM and IgG antibodies. As seen 
in Figure  5, the three hemocyanins (both native and deglyco-
sylated) activated the classical pathway of the human comple-
ment system, although a marked difference can be observed for 
native and deglycosylated FLH in all three donors. No activation 
was observed in the absence of patient serum or C1 (data not 
shown). No decrease in C4b deposition was observed upon CCH 
deglycosylation, an indication that the carbohydrate-binding IgG 
antibodies observed for D3 and D5 in Figure 4 do not activate 
the complement system.
Finally, to rule out unspecific interactions leading to C4b 
deposition, with the same C4b deposition assay, we used an 
anti-C1q-85 antibody, directed against the globular portions of 
C1q, thus preventing C1q binding to immunoglobulins and con-
sequent C1 activation (40). Due to a limited availability of anti-
C1q-85, this assay was performed with serum from D1, which 
consistently showed higher levels of C4b deposition. As shown 
on Figure 6, anti-C1q-85, even at the relatively low concentration 
of 2 µg/ml, decreased C4b deposition to levels similar to negative 
EDTA controls. Thus, as expected, the classical pathway activa-
tion described for hemocyanins is dependent on the C1 binding 
to immunoglobulins, further discarding alternative or unknown 
mechanisms, at least in these settings.
DiscUssiOn
In spite of the numerous biomedical and biotechnological 
applications for hemocyanins, especially for KLH (1, 2), 
molecular information to explain the potent immunomodula-
tory properties of these proteins is scarce. In this study we tested 
whether (i) natural antibodies described for KLH (26, 33) are 
also present against CCH and FLH, with emerging biomedical 
relevance and (ii) binding of these antibodies activates the clas-
sical pathway of the human complement system, as a possible 
hemocyanin-mediated immunomodulatory mechanism. We 
show here the presence of anti-KLH, anti-CCH, and anti-FLH 
natural antibodies in unimmunized, healthy donors, and that 
these antibodies activate the classical pathway of the comple-
ment system.
The results on Figure 1 agree with those obtained for KLH in 
other species (26, 27, 30) and we also detected FLH- and CCH-
binding antibodies in all donors. These results are explained, at 
least partly, by common structural characteristics of these hemo-
cyanins, such as shared preserved xenogeneic peptide sequences 
and the presence of mannose-rich structures, among other 
carbohydrates (6). These results announce the possibility that, in 
a large scale study, similar results may prevail. It would also be 
relevant to evaluate whether different levels of these antibodies, 
as seen in other species (29, 31), correlate with responses against 
pathogenic challenges or with differential responses against these 
hemocyanins. These evaluations should be experimentally per-
formed (i.e., against CCH, KLH, or FLH used as carrier proteins 
for antibody generation), and in therapeutic contexts, such as 
CCH, used as an adjuvant in antitumor dendritic cell vaccines or 
KLH in melanoma (42).
FigUre 2 | Unimmunized donors present natural antibodies against native and deglycosylated hemocyanins. The levels of immunoglobulins binding to 
keyhole limpet hemocyanin (KLH), Fissurella latimarginata hemocyanin (FLH), and Concholepas concholepas hemocyanin (CCH) and their deglycosylated 
counterparts [deglycosylated (oxidized) KLH (Ox-KLH), deglycosylated (oxidized) FLH (Ox-FLH), and deglycosylated (oxidized) CCH (Ox-CCH), respectively] were 
determined by an indirect ELISA in sera from unimmunized donors D1, D3, and D5. **p ≤ 0.01; ***p ≤ 0.001, assessed by a two-tailed Student’s t-test.
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Natural antibodies bind a wide range of carbohydrates 
(43–45), a situation similar to that observed for natural 
anti-KLH antibodies (46). However, when we performed the 
same assay with deglycosylated hemocyanins (Figure 2), only 
decreases in binding to KLH (especially in D3) and CCH were 
observed. Furthermore, differently from natural antibodies, 
FLH deglycosylation increased antibody binding in most 
donors, as reported by us for CCH in mice (47). Widely used, 
periodate-mediated deglycosylation is supposed to remove 
all types of carbohydrates. However, another glycosylated 
protein (48), subjected to periodate oxidation, still binds to 
specific lectins that recognize relevant carbohydrate epitopes. 
This indicates that the periodate oxidation could be actually 
unmasking carbohydrate epitopes, preventing the decrease of 
antibody binding and sometimes effectively increasing this type 
of binding. It is also feasible that due to a higher microhet-
erogeneity of N-linked sugars compared to KLH, and possibly 
residues of sialic acid, FLH presents a differential susceptibility 
to periodate-mediated deglycosylation. Future studies are in 
part aimed to elucidate this deglycosylation-induced antibody 
binding.
Natural antibodies usually belong to the IgM class and we 
detected this immunoglobulin class in all donors, recogniz-
ing both native and deglycosylated hemocyanins (Figure  3). 
However, similar to the previous experiment, deglycosylation led 
to an increase in binding to FLH and KLH. It is also relevant 
the fact that the presence of IgG natural antibodies recognizing 
KLH has also been described (26). Figure 4 shows that the sera 
from two donors (D3 and D5) recognize some hemocyanins. 
Differently from what occurs with IgM, in both cases, deglyco-
sylation does lead to a sharp decrease in reactivity, an indication 
that IgG antibodies in these donors are indeed directed against 
carbohydrates. However, their physiological relevance remains 
to be assessed since their levels seem to be lower as compared 
to IgM.
The levels of all these antibodies are relatively modest, as 
usually described for natural antibodies. As a comparison, 
P80, the positive control, a patient immunized with KLH in the 
context of a dendritic cell vaccine, has a much higher reactivity, 
even at the dilutions shown (1:100 in donors vs. 1:200 in P80). 
However, even at these low levels, natural antibodies can have 
a profound impact in early responses against pathogens (41). 
It also seems relevant that the reactivity observed for P202 
does not seem to be mediated by natural antibodies, since its 
IgG reactivity is much higher than those detected in sera from 
donors D3 and D5 (Figure 4). This is expected in an actively 
immunized patient.
Complement activation is a fundamental arm in immune 
responses, as both a danger signal detector and as an amplifi-
cation mechanism (34, 35). It has been reported that natural 
antibodies in human serum bind KLH, leading to C3 deposi-
tion (36). However, this report does not discriminate between 
the different activation pathways, although the alternative 
pathway is not efficiently activated by fluid phase molecules. 
This led us to perform experiments assessing the exclusive 
contribution of the classical pathway through a complement 
deposition assay with a reconstituted system, and with three 
different hemocyanins. Figure  5 shows that all hemocyanins 
activate the complement system in sera from all donors, and 
this activation is mediated by C1 binding to immunoglobulins 
(as seen in Figure 6), as classically described (35). For KLH and 
CCH, deglycosylation only led to minor changes in comple-
ment deposition for D1 and D3 donors, respectively. However, 
FLH deglycosylation, in agreement with the antibody-binding 
experiments, led to increased classical pathway-mediated 
complement activation in the three donors, indicating that at 
least some of the antibodies detected generate C1-binding sites. 
For D5 donor, even though IgG antibody binding diminishes 
upon deglycosylation, the latter does not affect complement 
deposition, indicating that these antibodies may belong to IgG 
subclasses that do not activate the complement system, such as 
IgG2 or IgG4.
Considering that natural antibodies activated the classical 
pathway of the complement system in the presence of hemocya-
nins, this adds a new potential explanation for the immunostimu-
latory properties of these proteins. Of course, more experiments, 
especially in vivo, are required to establish this as a physiologically 
relevant phenomenon. Future studies in our laboratories will 
FigUre 3 | Unimmunized donors present natural igM antibodies against native and deglycosylated hemocyanins. The levels of IgM immunoglobulins 
binding to keyhole limpet hemocyanin (KLH), Fissurella latimarginata hemocyanin (FLH), and Concholepas concholepas hemocyanin (CCH) and their deglycosylated 
counterparts [deglycosylated (oxidized) KLH (Ox-KLH), deglycosylated (oxidized) FLH (Ox-FLH), and deglycosylated (oxidized) CCH (Ox-CCH)] were determinated by 
an indirect ELISA in sera from five donors, using a specific anti-Fc5µ antibody. Serum from P202 was used as a positive control at a dilution of 1:250. *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001, assessed by a two-tailed Student’s t-test.
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address the possibility that the lectin pathways are activated by 
molluskan hemocyanins, since it is feasible that MBL and ficolins 
may bind to sugars present on these proteins.
Deglycosylated (oxidized) FLH actually shows increased 
antibody binding, and concomitantly increased complement 
deposition. Therefore, Ox-FLH could be considered a valid, 
FigUre 4 | Unimmunized donors present natural igg antibodies against native and deglycosylated hemocyanins. The levels of IgG immunoglobulins 
binding to keyhole limpet hemocyanin (KLH), Fissurella latimarginata hemocyanin (FLH) and Concholepas concholepas hemocyanin (CCH) and their deglycosylated 
counterparts [deglycosylated (oxidized) KLH (Ox-KLH), deglycosylated (oxidized) FLH (Ox-FLH), and deglycosylated (oxidized) CCH (Ox-CCH)] were determinated by 
an indirect ELISA in sera from five donors, using a specific anti-Fcγ antibody. Serum from P202 was used as a positive control at a dilution of 1:250. *p ≤ 0.05; 
***p ≤ 0.001, assessed by a two-tailed Student’s t-test.
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improved alternative for uses mediated by antibody binding 
and complement activation (e.g., as a carrier for monoclonal 
antibody generation). In addition, FLH, unlike KLH and CCH, 
is constituted by only one subunit (9), a convenience in a bio-
technological product, in terms of uniformity and amenability 
for GMP production.
FigUre 6 | The activation of the classical pathway of the human 
complement by hemocyanins depends on c1 binding to 
immunoglobulins. A C4b deposition assay was used to determine the 
activation of the classical pathway when keyhole limpet hemocyanin (KLH), 
Fissurella latimarginata hemocyanin (FLH), Concholepas concholepas 
hemocyanin (CCH), and their deglycosylated counterparts [deglycosylated 
(oxidized) KLH (Ox-KLH), deglycosylated (oxidized) FLH (Ox-FLH), and 
deglycosylated (oxidized) CCH (Ox-CCH)] were incubated with sera from D1, 
in conditions similar to those used in the previous experiments, or in the 
presence of EDTA (classical and lectin pathway inhibitor) or anti-C1q-85 (an 
antibody that prevents C1q binding to Fc regions of immunoglobulins). 
**p ≤ 0.01; ***p ≤ 0.001, assessed by a two-tailed Student’s t-test.
FigUre 5 | sera from unimmunized donors interact with hemocyanins and activate in vitro the classical pathway of the human complement system. 
A C4b deposition assay was used to determine the activation of the classical pathway when keyhole limpet hemocyanin (KLH), Fissurella latimarginata hemocyanin 
(FLH), Concholepas concholepas hemocyanin (CCH), and their deglycosylated counterparts [deglycosylated (oxidized) KLH (Ox-KLH), deglycosylated (oxidized) FLH 
(Ox-FLH), and deglycosylated (oxidized) CCH (Ox-CCH)] were incubated with sera from three unimmunized donors, at a dilution of 1:60 and human purified IgM was 
used as a positive control. *p ≤ 0.05; ***p ≤ 0.001, assessed by a two-tailed Student’s t-test.
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and FLH, with emerging biomedical relevance. This information 
opens a number of possibilities for further studies that may prove 
useful in the design of better hemocyanin-based research tools, 
for diagnosis and immunotherapy.
aUThOr cOnTriBUTiOns
Conception and design: JP-B, CV, AF, and MB. Performed the 
experiments and data acquisition: JP-B, LA-G, ES-R, and GV. 
Data analysis and interpretation: JP-B, IM, LA-G, ES-R, GV, CV, 
AF, and MB. Production of critical reactives: IM, ML, FS-O, MB, 
and AF. Manuscript writing: JP-B, AF, and MB. All the authors 
read and approved the final version of this manuscript.
acKnOWleDgMenTs
The authors thank Dr. Diana Wouters (Immunopathology 
Department, Sanquin Blood Supply Foundation, Amsterdam, 
The Netherlands) for providing anti-C1q-85. The authors also 
thank Fabián Tempio for valuable help with patient sera and 
Ruth Mora and Juana Orellana for their exceptional technical 
assistance.
FUnDing
This study was supported by CONICYT-CHILE FONDECYT 
Regular Grants: 1130099 (AF), 1110651 and 1151337 (MB). A 
CONICYT-CHILE National Fellowship (221320366) for Master 
Studies was awarded to JP-B.
In synthesis, this work proposes a potential mechanism 
that could contribute to the immunomodulatory properties of 
molluskan hemocyanins, by describing natural, complement-
activating antibodies reacting with hemocyanins such as CCH 
reFerences
1. Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. 
Micron (1999) 30:597–623. 
2. Coates CJ, Nairn J. Diverse immune functions of hemocyanins. Dev Comp 
Immunol (2014) 45:43–55. doi:10.1016/j.dci.2014.01.021 
3. Markl J. Evolution of molluscan hemocyanin structures. Biochim Biophys Acta 
(2013) 1834:1840–52. doi:10.1016/j.bbapap.2013.02.020 
4. Lieb B, Gebauer W, Gatsogiannis C, Depoix F, Hellmann N, Harasewych 
MG, et  al. Molluscan mega-hemocyanin: an ancient oxygen carrier tuned 
by a ~550 kDa polypeptide. Front Zool (2010) 7:14. doi:10.1186/1742- 
9994-7-14 
9Pizarro-Bauerle et al. Hemocyanins Activate Complement through Natural Antibodies
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 188
5. Gatsogiannis C, Hofnagel O, Markl J, Raunser S. Structure of mega- 
hemocyanin reveals protein origami in snails. Structure (2015) 23:93–103. 
doi:10.1016/j.str.2014.10.013 
6. Becker MI, Arancibia S, Salazar F, Del Campo M, De Ioannes A. Mollusk 
hemocyanins as natural immunostimulants in biomedical applications. In: 
DucGHT, editor. Immune Response Activation. Rijeka, Croatia: InTech (2014). 
p. 45–72.
7. Arancibia S, Salazar F, Becker MI. Hemocyanins in the immunotherapy of 
superficial bladder cancer. In:  CandaA, editor. Bladder Cancer – From Basic 
to Robotic Surgery. Rijeka, Croatia: InTech (2012). p. 221–42.
8. De Ioannes P, Moltedo B, Oliva H, Pacheco R, Faunes F, De Ioannes AE, 
et  al. Hemocyanin of the molluscan Concholepas concholepas exhibits an 
unusual heterodecameric array of subunits. J Biol Chem (2004) 279:26134–42. 
doi:10.1074/jbc.M400903200 
9. Arancibia S, Espinoza C, Salazar  F, Del Campo  M, Tampe R, Zhong TY, 
et  al. A novel immunomodulatory hemocyanin from the limpet Fissurella 
latimarginata promotes potent anti-tumor activity in melanoma. PLoS One 
(2014) 9:e87240. doi:10.1371/journal.pone.0087240 
10. Moltedo B, Faunes F, Haussmann D, De Ioannes P, De Ioannes AE, Puente 
J, et  al. Immunotherapeutic effect of Concholepas hemocyanin in the 
murine bladder cancer model: evidence for conserved antitumor properties 
among hemocyanins. J Urol (2006) 176:2690–5. doi:10.1016/j.juro.2006. 
07.136 
11. Arancibia S, Del Campo M, Nova E, Salazar F, Becker MI. Enhanced struc-
tural stability of Concholepas hemocyanin increases its immunogenicity and 
maintains its non-specific immunostimulatory effects. Eur J Immunol (2012) 
42:688–99. doi:10.1002/eji.201142011 
12. Manosalva H, De Ioannes AE, Becker MI. Development of monoclonal anti-
bodies bearing the internal image of the gizzerosine epitope and application 
in a competitive ELISA for fish meal. Hybrid Hybridomics (2004) 23:45–54. 
doi:10.1089/153685904322772024 
13. Matus S, Burgos PV, Bravo-Zehnder M, Kraft R, Porras OH, Farías P, et al. 
Antiribosomal-P autoantibodies from psychiatric lupus target a novel neu-
ronal surface protein causing calcium influx and apoptosis. J Exp Med (2007) 
204:3221–34. doi:10.1084/jem.20071285 
14. Corvalán LA, Araya R, Brañes MC, Sáez PJ, Kalergis AM, Tobar JA, et  al. 
Injury of skeletal muscle and specific cytokines induce the expression of gap 
junction channels in mouse dendritic cells. J Cell Physiol (2007) 211:649–60. 
doi:10.1002/jcp.20971 
15. Gravotta D, Deora A, Perret E, Oyanadel C, Soza A, Schreiner R, et  al. 
AP1B sorts basolateral proteins in recycling and biosynthetic routes of 
MDCK cells. Proc Natl Acad Sci U S A (2007) 104:1564–9. doi:10.1073/pnas. 
0610700104 
16. Becker MI, De Ioannes AE, León C, Ebensperger LA. Females of the 
communally breeding rodent, Octodon degus, transfer antibodies to their 
offspring during pregnancy and lactation. J Reprod Immunol (2007) 74:68–77. 
doi:10.1016/j.jri.2007.01.002 
17. Ebensperger LA, León C, Ramírez-Estrada J, Abades S, Hayes LD, Nova E, 
et al. Immunocompetence of breeding females is sensitive to cortisol levels but 
not to communal rearing in the degu (Octodon degus). Physiol Behav (2015) 
140:61–70. doi:10.1016/j.physbeh.2014.12.028 
18. Pilon J, Loiacono C, Okeson D, Lund S, Vercauteren K, Rhyan J, et al. Anti-
prion activity generated by a novel vaccine formulation. Neurosci Lett (2007) 
429:161–4. doi:10.1016/j.neulet.2007.10.015 
19. Benka VAW, Levy JK. Vaccines for feline contraception: GonaCon GnRH-
hemocyanin conjugate immunocontraceptive. J Feline Med Surg (2015) 
17:758–65. doi:10.1177/1098612X15594989 
20. Reyes D, Salazar L, Espinoza E, Pereda C, Castellón E, Valdevenito R, et al. 
Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and 
memory immune response in castration-resistant prostate cancer patients. 
Br J Cancer (2013) 109:1488–97. doi:10.1038/bjc.2013.494 
21. Becker MI, Fuentes A, Del Campo  M, Manubens A, Nova E, Oliva H, et al. 
Immunodominant role of CCHA subunit of Concholepas hemocyanin is 
associated with unique biochemical properties. Int Immunopharmacol (2009) 
9:330–9. doi:10.1016/j.intimp.2008.12.011 
22. Tchorbanov A, Idakieva K, Mihaylova N, Doumanova L. Modulation 
of the immune response using Rapana thomasiana hemocyanin. Int 
Immunopharmacol (2008) 8:1033–8. doi:10.1016/j.intimp.2008.03.008 
23. Wirguin I, Suturkova-Milosević L, Briani C, Latov N. Keyhole limpet hemo-
cyanin contains Gal(β1-3) GalNAc determinants that are cross-reactive with 
the T antigen. Cancer Immunol Immunother (1995) 40:307–10. 
24. Presicce P, Taddeo A, Conti A, Villa ML, Della Bella S. Keyhole limpet 
hemocyanin induces the activation and maturation of human dendritic 
cells through the involvement of mannose receptor. Mol Immunol (2008) 
45:1136–45. doi:10.1016/j.molimm.2007.07.020 
25. Zhong T, Arancibia S, Born R, Tampe R, Villar J, Del Campo M, et  al. 
Hemocyanins stimulate innate immunity by inducing different temporal 
patterns of proinflammatory cytokine expression in macrophages. J Immunol 
(2016) 196:4650–62. doi:10.4049/jimmunol.1501156 
26. Moroz LA, Krygier V, Kotoulas A. Normal human IgG with antibody activity 
for keyhole limpet haemocyanin. Immunology (1973) 25:441–9. 
27. Star L, Frankena K, Kemp B, Nieuwland MGB, Parmentier HK. Natural 
humoral immune competence and survival in layers. Poult Sci (2007) 
86:1090–9. doi:10.1093/PS/86.6.1090 
28. Bao M, Bovenhuis H, Nieuwland MGB, Parmentier HK, van der Poel 
JJ. Genetic parameters of IgM and IgG antibodies binding autoantigens in 
healthy chickens. Poult Sci (2016) 95:458–65. doi:10.3382/ps/pev347 
29. Berghof TV, van der Klein SA, Arts JA, Parmentier HK, van der Poel JJ, 
Bovenhuis H. Genetic and non-genetic inheritance of natural antibodies 
binding keyhole limpet hemocyanin in a purebred layer chicken line. PLoS 
One (2015) 10:e0131088. doi:10.1371/journal.pone.0131088 
30. de Klerk B, Ducro BJ, Heuven HC, den Uyl I, van Arendonk JA, Parmentier 
HK, et al. Phenotypic and genetic relationships of bovine natural antibodies 
binding keyhole limpet hemocyanin in plasma and milk. J Dairy Sci (2015) 
98:2746–52. doi:10.3168/jds.2014-8818 
31. van Altena SE, Peen MA, van der Linden FH, Parmentier HK, Savelkoul HF, 
Tijhaar EJ. Bovine natural antibodies in antibody-dependent bactericidal activ-
ity against Escherichia coli and Salmonella Typhimurium and risk of mastitis. Vet 
Immunol Immunopathol (2016) 171:21–7. doi:10.1016/j.vetimm.2016.01.009 
32. Hersh EM, Dyre SE. Cells binding the antigen keyhole limpet haemocyanin 
in the peripheral blood and in the lymphocyte cultures of non-immune and 
immunized human subjects. Clin Exp Immunol (1974) 17:299–309. 
33. Burke GP, Smith KA, Rachel Stocking IG, Ferm M, McIntyre OR. Anti-keyhole 
limpet hemocyanin antibody in normal unsensitized individuals. J Allergy 
Clin Immunol (1977) 59:309–13. 
34. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system 
for immune surveillance and homeostasis. Nat Immunol (2010) 11:785–97. 
doi:10.1038/ni.1923 
35. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement 
system part I – molecular mechanisms of activation and regulation. Front 
Immunol (2015) 6:262. doi:10.3389/fimmu.2015.00262 
36. Thornton BP, Vĕtvicka V, Ross GD. Natural antibody and complement-medi-
ated antigen processing and presentation by B lymphocytes. J Immunol (1994) 
152:1727–37. 
37. Bradford MM. A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding. Anal 
Biochem (1976) 72:248–54. 
38. López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE, et  al. 
Prolonged survival of dendritic cell-vaccinated melanoma patients correlates 
with tumor-specific delayed type IV hypersensitivity response and reduction 
of tumor growth factor β-expressing T cells. J Clin Oncol (2009) 27:945–52. 
doi:10.1200/JCO.2008.18.0794 
39. González FE, Gleisner A, Falcón-Beas F, Osorio F, López MN, Salazar-Onfray 
F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum 
Vaccin Immunother (2014) 10:3261–9. doi:10.4161/21645515.2014.982996 
40. Roos A, Nauta AJ, Broers D, Faber-Krol MC, Trouw LA, Drijfhout JW, et al. 
Specific inhibition of the classical complement pathway by C1q-binding 
peptides. J Immunol (2001) 167:7052–9. doi:10.4049/jimmunol.167.12.7052 
41. Ochsenbein AF, Zinkernagel RM. Natural antibodies and complement link 
innate and acquired immunity. Immunol Today (2000) 21:624–30. doi:10.1016/
s0167-5699(00)01754-0 
42. Aarntzen EH, de Vries IJ, Göertz JH, Beldhuis-Valkis M, Brouwers HM, van 
de Rakt MW, et al. Humoral anti-KLH responses in cancer patients treated 
with dendritic cell-based immunotherapy are dictated by different vaccination 
parameters. Cancer Immunol Immunother (2012) 61:2003–11. doi:10.1007/
s00262-012-1263-z 
10
Pizarro-Bauerle et al. Hemocyanins Activate Complement through Natural Antibodies
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 188
43. Bos NA, Kimura H, Meeuwsen CG, De Visser H, Hazenberg MP, Wostmann 
BS, et al. Serum immunoglobulin levels and naturally occurring antibodies 
against carbohydrate antigens in germ-free BALB/c mice fed chemically 
defined ultrafiltered diet. Eur J Immunol (1989) 19:2335–9. 
44. Boes M. Role of natural and immune IgM antibodies in immune responses. 
Mol Immunol (2001) 37:1141–9. doi:10.1016/S0161-5890(01)00025-6  
45. Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, 
protector and regulator. Nat Rev Immunol (2010) 10:778–86. doi:10.1038/ 
nri2849 
46. Oyelaran O, Gildersleeve JC. Evaluation of human antibody responses to 
keyhole limpet hemocyanin on a carbohydrate microarray. Proteomics Clin 
Appl (2010) 4:285–94. doi:10.1002/prca.200900130 
47. Oliva H, Moltedo B, De Ioannes P, Faunes F, De Ioannes AE, Becker MI. 
Monoclonal antibodies to molluskan hemocyanin from Concholepas concho-
lepas demonstrate common and specific epitopes among subunits. Hybrid 
Hybridomics (2002) 21:365–74. doi:10.1089/153685902761022715 
48. Leito JTD, Ligtenberg AJM, van Houdt M, van den Berg TK, Wouters D. 
The bacteria binding glycoprotein salivary agglutinin (SAG/gp340) acti-
vates complement via the lectin pathway. Mol Immunol (2011) 49:185–90. 
doi:10.1016/j.molimm.2011.08.010 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Pizarro-Bauerle, Maldonado, Sosoniuk-Roche, Vallejos, López, 
Salazar-Onfray, Aguilar-Guzmán, Valck, Ferreira and Becker. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
